Table 4.
Multivariate analysis of chemoradiation vs. radiation.
| Patient Characteristics | OR | 95% CI | p-value | |
|---|---|---|---|---|
| SEER region (ref.= Connecticut and New Jersey) |
Detroit | 1.78** | (1.49 – 2.12) | <.0001 |
| Hawaii | 0.38** | (0.23 – 0.62) | 0.0001 | |
| Atlanta and Rural Georgia |
0.78 | (0.60 – 1.02) | 0.0707 | |
| San Francisco, San Jose, LA and Greater California |
0.83** | (0.71 – 0.95) | 0.0095 | |
| Louisiana | 0.71** | (0.57 – 0.89) | 0.0033 | |
| Cancer site (ref.= Oral Cavity) | Hypopharynx + Larynx | 0.79** | (0.69 – 0.90) | 0.0006 |
| Tonsil + Oropharynx | 1.63** | (1.35 – 1.96) | <.0001 | |
| Salivary Gland, Nasopharynx + Middle Ear |
1.05 | (0.87 – 1.28) | 0.5875 | |
| Diagnosis era (ref.= 2002– 2007) |
1997–2001 | 0.47** | (0.41 – 0.54) | <.0001 |
| 1992–1996 | 0.20** | (0.17 – 0.23) | <.0001 | |
| Historic stage A (ref.= In Situ and localized) |
Regional | 5.66** | (4.90 – 6.54) | <.0001 |
| Locally advanced | 8.07** | (6.51 – 10.00) | <.0001 | |
| Unknown/Unstaged | 3.32** | (2.54 – 4.34) | <.0001 | |
| Charlson comorbidity index (ref.= 0) |
1+ | 0.93 | (0.83 – 1.04) | 0.2035 |
| Sex (ref.= Male) | Female | 0.79** | (0.69 – 0.90) | 0.0003 |
| Race (ref.= Caucasian American) |
Non-Caucasian American |
1.09 | (0.91 – 1.30) | 0.3431 |
| Age at diagnosis | 0.94** | (0.93 – 0.94) | <.0001 | |
| Marital status (ref.= Married) | Unmarried or Unknown | 0.95 | (0.84 – 1.08) | 0.4296 |
| Dual eligibility for Medicare/Medicaid (ref.= No) |
Yes | 1.08 | (0.92 – 1.28) | 0.3375 |
| Percent of high school graduate based on 2000 census data (ref. = Quartile 4: <25%) |
Quartile 1: >=75% | 1.05 | (0.88 – 1.24) | 0.5881 |
| Quartile 2: 50%–<75% | 1.06 | (0.90 – 1.25) | 0.4816 | |
| Quartile 3: 25%–<50% | 0.97 | (0.83 – 1.14) | 0.7398 | |
| Cooperative group affiliated | 0.99 | (0.87 – 1.12) | 0.8273 | |
| NCI cancer center designated | 1.04 | (0.74 – 1.47) | 0.8162 | |
| Medical school affiliation | 0.94 | (0.82 – 1.06) | 0.3107 | |